8-K: Vivani Secures $10M Equity, Advances Semaglutide Implant

Vivani Medical, Inc. announced a $10 million equity financing to accelerate its semaglutide implant program, NPM-139, following positive preclinical and clinical data, alongside reporting Q2 2025 financial results and plans for a Cortigent spin-off.

Summary

• Secured approximately $10.0 million in gross proceeds from a private placement of 7,936,507 common shares priced at $1.26 per share.
• The financing is expected to secure the company's financial position into the second half of 2026.
• Proceeds will accelerate the development of NPM-139, a semaglutide implant for chronic weight management.
• NPM-139 preclinical data showed approximately 20% weight loss maintained for over six months with a single implant, supporting the potential for annual dosing.
• The LIBERATE-1 Phase 1 clinical study of NPM-115 (exenatide implant) met primary objectives with a positive safety and tolerability profile and encouraging performance data.
• Plans to spin off Cortigent, Inc., a division developing brain implant devices, as an independent publicly traded company in Q3 or Q4 2025.
• Reported a net loss of $7.1 million for the three months ended June 30, 2025, compared to $5.3 million for the same period in 2024.
• Cash, cash equivalents, and restricted cash totaled $8.1 million as of June 30, 2025, a decrease from $19.7 million on December 31, 2024.
• Research and development expense increased by 35% to $4.8 million in Q2 2025 from $3.5 million in Q2 2024.
• General and administrative expense increased by 25% to $2.7 million in Q2 2025 from $2.2 million in Q2 2024.
• Anthony Baldor was appointed as Chief Financial Officer on June 11, 2025.
• Expanded collaboration with Okava Pharmaceuticals, Inc. to include dogs for OKV-119, a long-acting GLP-1 therapy.

Sentiment

Score: 7

Explanation: The filing presents a mixed but generally positive outlook. The significant equity financing and positive preclinical/clinical data for key pipeline assets (NPM-139, NPM-115) are strong positives, extending the financial runway and validating the NanoPortal platform. The strategic focus on semaglutide and the planned Cortigent spin-off are also favorable. However, the worsening Q2 financial results with increased net loss and cash burn temper the overall sentiment, indicating ongoing operational expenses and reliance on external funding.

Positives

• Secured $10.0 million in new equity financing, extending the financial runway into the second half of 2026.
• The private placement was executed without warrants, discounts, or placement agent fees, indicating favorable terms.
• Positive preclinical data for NPM-139 demonstrated approximately 20% weight loss maintained for over six months with a single implant, supporting potential for annual dosing.
• The LIBERATE-1 Phase 1 clinical study for NPM-115 showed a positive safety and tolerability profile and encouraging performance, meeting primary objectives.
• Strategic prioritization of NPM-139, a semaglutide implant, aligns with the growing and widely adopted semaglutide market.
• Planned spin-off of Cortigent, Inc. could unlock value for shareholders by creating two focused entities.
• Appointment of Anthony Baldor as CFO brings over 20 years of biotechnology financial management experience.

Negatives

• Significant decrease in cash balance to $8.1 million as of June 30, 2025, from $19.7 million on December 31, 2024, reflecting substantial cash burn.
• Net loss increased to $7.1 million in Q2 2025 from $5.3 million in Q2 2024, indicating worsening profitability.
• Research and development expenses increased by 35% and general and administrative expenses by 25% year-over-year, contributing to higher operating losses.
• Continued reliance on equity financing for operational funding, with three equity purchase agreements totaling $21.25 million committed through July 2026.

Risks

• Risks related to the development and commercialization of product candidates, including NPM-139 and NPM-115.
• Potential for delays and changes in product development due to applicable laws, regulations, guidelines, and regulatory clearance or approval processes.
• Uncertainty regarding the ability to commence clinical development of NPM-139 as anticipated.
• Risks associated with the initiation, enrollment, and conduct of planned clinical trials and the outcomes therefrom.
• History of losses and the ongoing need to access additional capital to fund business operations.
• Market conditions and the ability of Cortigent to successfully complete its proposed spin-out as an independent publicly traded company.
• Additional risks that the company considers immaterial or which are currently unknown.

Future Outlook

Vivani anticipates providing a more detailed NPM-139 program update later this year, including the proposed design of the clinical program through a dose-ranging weight maintenance study outcome. Clinical development of NPM-139 is expected to initiate in 2026. The spin-off of Cortigent, Inc. as an independent publicly traded company is anticipated to be completed in the third or fourth quarter of 2025. The recent $10 million equity financing is expected to secure the company's financial position into the second half of 2026.

Management Comments

• Vivani Chairman of the Board Gregg Williams stated, "Today's financing announcement reinforces my enthusiasm about the recent progress and future prospects of NanoPortal drug implants as well as my confidence in the management team to successfully develop and deliver transformational therapeutic options for the treatment of chronic diseases, starting with obesity and type 2 diabetes. I remain committed to supporting the Company's efforts to continue advancing development of its pipeline based on the recent, very positive developments."
• Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "Our strategic prioritization of the semaglutide implant NPM-139 provides Vivani with significantly improved prospects regarding both technical success and commercial potential considering the clinical evidence, broad adoption, and continued growth of semaglutide-based products into the foreseeable future. Our rapid advancement of NPM-139 toward clinical-stage development is supported by two recent achievements within our R&D programs, namely, the success of LIBERATE-1 and the positive preclinical weight loss data generated with NPM-139."
• Dr. Mendelsohn added, "As the first-in-human application of Vivani's NanoPortal implant technology, it was important that LIBERATE-1 showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study's primary objectives. Concurrently, newly generated NPM-139 preclinical feasibility data showed approximately 20% weight loss was maintained longer than six months with a single implant in an ongoing study, continuing to support the potential for annual dosing. We anticipate initiating the NPM-139 clinical program in 2026."

Industry Context

The announcement highlights Vivani's strategic focus on semaglutide-based products, aligning with the significant clinical evidence, broad adoption, and continued growth of GLP-1 therapies in the obesity and type 2 diabetes markets. The company's NanoPortal implant technology aims to address medication non-adherence, a widespread issue affecting approximately 50% of patients, by offering ultra long-acting drug delivery, potentially improving patient tolerance and efficacy compared to daily or weekly administrations. The planned spin-off of Cortigent, focused on neurostimulation, positions Vivani to concentrate on its biopharmaceutical pipeline while allowing Cortigent to pursue its specialized market for brain implant devices.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or projects with detailed results for direct comparison.
• The preclinical data for NPM-139, showing approximately 20% weight loss maintained for over six months with a single implant, suggests a competitive advantage in terms of sustained efficacy and potential for annual dosing, which could differentiate it from existing daily or weekly GLP-1 injectables like Ozempic (semaglutide) or Wegovy (semaglutide).
• The positive safety and tolerability profile of NPM-115 in its first-in-human Phase 1 study is a crucial validation for Vivani's NanoPortal implant technology, indicating its potential for broader application across various drug molecules.
• The focus on long-acting implants directly addresses the industry-wide challenge of medication non-adherence, which affects a significant portion of patients on chronic therapies.

Management Changes

Legal Proceedings

• A litigation accrual of $1,675 thousand is reported as of June 30, 2025, and December 31, 2024.
• No new material actions, suits, proceedings, or investigations are pending or threatened beyond what is set forth in SEC Reports.

Related Party Transactions

• One of the purchasers in the $10.0 million equity financing is an entity affiliated with a director (Gregg Williams).

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares but benefit from extended financial runway, accelerated pipeline development (NPM-139), validation of technology (LIBERATE-1), and potential value creation from the Cortigent spin-off.
• Patients: Potential for new, ultra long-acting treatment options for chronic diseases like obesity and type 2 diabetes, aiming to improve adherence and efficacy.
• Employees: Enhanced job security and continued opportunities due to extended financial runway and active pipeline development.
• Creditors: Improved financial stability due to the capital raise, reducing immediate liquidity concerns.
• Suppliers/Partners: Continued business opportunities and stability due to the company's extended financial position and ongoing R&D activities, including the expanded collaboration with Okava Pharmaceuticals.

Next Steps

• Provide a more detailed NPM-139 program update later this year, including proposed clinical program design.
• Initiate clinical development of NPM-139 in 2026.
• Complete the spin-off of Cortigent, Inc. as an independent publicly traded company in the third or fourth quarter of 2025.
• Continue to receive committed capital contributions totaling $21.25 million through July 2026 from equity purchase agreements.

Key Dates

Recommendation

The significant capital raise and positive preclinical/clinical data for key pipeline assets are strong catalysts, providing a longer financial runway and validating the core technology. The strategic focus on the high-growth GLP-1 market and the planned spin-off of Cortigent could unlock substantial value. However, the worsening Q2 financial results, characterized by increased net loss and cash burn, indicate ongoing operational challenges and a continued reliance on external funding. While the long-term potential is promising, the current financial performance suggests a 'hold' position until further clinical milestones are achieved and financial stability improves, balancing the positive strategic moves with the immediate financial headwinds.

Keywords

Vivani Medical, VANI, biopharmaceutical, drug implants, semaglutide, NPM-139, obesity, weight management, type 2 diabetes, GLP-1, NanoPortal, Cortigent, spin-off, equity financing, private placement, clinical trials, preclinical data, biotech, pharmaceuticals